• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性肾脏病患者中产生尿毒症毒素前体的肠道细菌的分离和定量。

Isolation and Quantification of Uremic Toxin Precursor-Generating Gut Bacteria in Chronic Kidney Disease Patients.

机构信息

Department of Internal Medicine and Pediatrics, Nephrology Section, Ghent University Hospital, 9000 Ghent, Belgium.

Department of Diagnostic Sciences, Laboratory Bacteriology Research, Ghent University, 9000 Ghent, Belgium.

出版信息

Int J Mol Sci. 2020 Mar 14;21(6):1986. doi: 10.3390/ijms21061986.

DOI:10.3390/ijms21061986
PMID:32183306
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7139965/
Abstract

In chronic kidney disease (CKD), impaired kidney function results in accumulation of uremic toxins, which exert deleterious biological effects and contribute to inflammation and cardiovascular morbidity and mortality. Protein-bound uremic toxins (PBUTs), such as -cresyl sulfate, indoxyl sulfate and indole-3-acetic acid, originate from phenolic and indolic compounds, which are end products of gut bacterial metabolization of aromatic amino acids (AAA). This study investigates gut microbial composition at different CKD stages by isolating, identifying and quantifying PBUT precursor-generating bacteria. Fecal DNA extracts from 14 controls and 138 CKD patients were used to quantify total bacterial number and 11 bacterial taxa with qPCR. Moreover, isolated bacteria from CKD 1 and CKD 5 fecal samples were cultured in broth medium supplemented with AAA under aerobic and anaerobic conditions, and classified as PBUT precursor-generators based on their generation capacity of phenolic and indolic compounds, measured with U(H)PLC. In total, 148 different fecal bacterial species were isolated, of which 92 were PBUT precursor-generators. These bacterial species can be a potential target for reducing PBUT plasma levels in CKD. qPCR indicated lower abundance of short chain fatty acid-generating bacteria, spp. and spp., and higher and with impaired kidney function, confirming an altered gut microbial composition in CKD.

摘要

在慢性肾脏病(CKD)中,肾脏功能受损会导致尿毒症毒素的积累,这些毒素会产生有害的生物学效应,并导致炎症和心血管发病率和死亡率增加。蛋白结合尿毒症毒素(PBUT),如 - 甲苯磺酸、吲哚硫酸和吲哚-3-乙酸,来源于酚类和吲哚类化合物,这些化合物是肠道细菌代谢芳香族氨基酸(AAA)的终产物。本研究通过分离、鉴定和定量产生 PBUT 前体的细菌,来研究不同 CKD 阶段的肠道微生物组成。使用 qPCR 从 14 名对照者和 138 名 CKD 患者的粪便 DNA 提取物中定量总细菌数和 11 种细菌分类群。此外,从 CKD 1 和 CKD 5 粪便样本中分离出的细菌在有氧和厌氧条件下的富含 AAA 的肉汤培养基中培养,并根据其产生酚类和吲哚类化合物的能力进行分类,用 U(H)PLC 进行测量。总共分离出 148 种不同的粪便细菌,其中 92 种是 PBUT 前体生成菌。这些细菌可能是降低 CKD 患者血浆中 PBUT 水平的潜在目标。qPCR 表明,随着肾功能受损,短链脂肪酸生成菌、 spp. 和 spp. 的丰度降低, 和 增加,这证实了 CKD 患者肠道微生物组成的改变。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/879b/7139965/19c6d2b99e3a/ijms-21-01986-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/879b/7139965/f05eb50346af/ijms-21-01986-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/879b/7139965/19c6d2b99e3a/ijms-21-01986-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/879b/7139965/f05eb50346af/ijms-21-01986-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/879b/7139965/19c6d2b99e3a/ijms-21-01986-g002.jpg

相似文献

1
Isolation and Quantification of Uremic Toxin Precursor-Generating Gut Bacteria in Chronic Kidney Disease Patients.慢性肾脏病患者中产生尿毒症毒素前体的肠道细菌的分离和定量。
Int J Mol Sci. 2020 Mar 14;21(6):1986. doi: 10.3390/ijms21061986.
2
Gut microbiota generation of protein-bound uremic toxins and related metabolites is not altered at different stages of chronic kidney disease.在慢性肾脏病的不同阶段,肠道微生物群产生蛋白质结合型尿毒症毒素及相关代谢产物的情况并未改变。
Kidney Int. 2020 Jun;97(6):1230-1242. doi: 10.1016/j.kint.2020.01.028. Epub 2020 Feb 17.
3
Exploring binding characteristics and the related competition of different protein-bound uremic toxins.探索不同蛋白结合型尿毒症毒素的结合特性及相关竞争性。
Biochimie. 2017 Aug;139:20-26. doi: 10.1016/j.biochi.2017.05.010. Epub 2017 May 17.
4
Protein-Bound Uremic Toxins and Immunity.蛋白结合型尿毒症毒素与免疫
Methods Mol Biol. 2021;2325:215-227. doi: 10.1007/978-1-0716-1507-2_15.
5
Gut Microbiota and Their Derived Metabolites, a Search for Potential Targets to Limit Accumulation of Protein-Bound Uremic Toxins in Chronic Kidney Disease.肠道微生物群及其衍生代谢物,寻找限制慢性肾脏病中蛋白结合尿毒症毒素积累的潜在靶点。
Toxins (Basel). 2021 Nov 17;13(11):809. doi: 10.3390/toxins13110809.
6
Impacts of Indoxyl Sulfate and p-Cresol Sulfate on Chronic Kidney Disease and Mitigating Effects of AST-120.对慢性肾脏病的影响以及 AST-120 的缓解作用。
Toxins (Basel). 2018 Sep 11;10(9):367. doi: 10.3390/toxins10090367.
7
The Effect of Sevelamer on Serum Levels of Gut-Derived Uremic Toxins: Results from In Vitro Experiments and A Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trial.盐酸司维拉姆对肠道来源尿毒症毒素血清水平的影响:来自体外实验和多中心、双盲、安慰剂对照、随机临床试验的结果。
Toxins (Basel). 2019 May 17;11(5):279. doi: 10.3390/toxins11050279.
8
Adsorption of Protein-Bound Uremic Toxins Through Direct Hemoperfusion With Hexadecyl-Immobilized Cellulose Beads in Patients Undergoing Hemodialysis.在接受血液透析的患者中,通过用十六烷基固定化纤维素珠进行直接血液灌流吸附蛋白结合型尿毒症毒素。
Artif Organs. 2018 Jan;42(1):88-93. doi: 10.1111/aor.12961. Epub 2017 Jul 13.
9
Protein-bound uremic toxins: new culprits of cardiovascular events in chronic kidney disease patients.蛋白结合型尿毒症毒素:慢性肾脏病患者心血管事件的新罪魁祸首。
Toxins (Basel). 2014 Feb 20;6(2):665-78. doi: 10.3390/toxins6020665.
10
Does Low-Protein Diet Influence the Uremic Toxin Serum Levels From the Gut Microbiota in Nondialysis Chronic Kidney Disease Patients?低蛋白饮食是否会影响非透析慢性肾脏病患者肠道微生物群产生的尿毒症毒素血清水平?
J Ren Nutr. 2018 May;28(3):208-214. doi: 10.1053/j.jrn.2017.11.007. Epub 2018 Feb 10.

引用本文的文献

1
The effects of Shenkang suppository on kidney function and gut microbiota in nondialysis patients with chronic kidney disease stages 3-4: A randomized controlled trial.肾康栓对3-4期非透析慢性肾脏病患者肾功能及肠道微生物群的影响:一项随机对照试验
Front Pharmacol. 2025 Jul 29;16:1621208. doi: 10.3389/fphar.2025.1621208. eCollection 2025.
2
A bibliometric study of global trends in diabetic nephropathy and intestinal flora research.糖尿病肾病与肠道菌群研究全球趋势的文献计量学分析
Front Microbiol. 2025 May 21;16:1577703. doi: 10.3389/fmicb.2025.1577703. eCollection 2025.
3
Odoribacter splanchnicus-A Next-Generation Probiotic Candidate.

本文引用的文献

1
Gut microbiota generation of protein-bound uremic toxins and related metabolites is not altered at different stages of chronic kidney disease.在慢性肾脏病的不同阶段,肠道微生物群产生蛋白质结合型尿毒症毒素及相关代谢产物的情况并未改变。
Kidney Int. 2020 Jun;97(6):1230-1242. doi: 10.1016/j.kint.2020.01.028. Epub 2020 Feb 17.
2
Comparison of five assays for DNA extraction from bacterial cells in human faecal samples.比较从人粪便样本中的细菌细胞中提取 DNA 的五种检测方法。
J Appl Microbiol. 2020 Aug;129(2):378-388. doi: 10.1111/jam.14608. Epub 2020 Feb 20.
3
Tryptophan Metabolism by Gut Microbiome and Gut-Brain-Axis: An Analysis.
内脏气味杆菌——下一代益生菌候选菌株
Microorganisms. 2025 Apr 3;13(4):815. doi: 10.3390/microorganisms13040815.
4
Short-Chain Fatty Acids and Their Metabolic Interactions in Heart Failure.心力衰竭中的短链脂肪酸及其代谢相互作用
Biomedicines. 2025 Feb 3;13(2):343. doi: 10.3390/biomedicines13020343.
5
Gut microbiota and kidney function in autosomal dominant polycystic kidney disease participants in Cameroon: a cross-sectional study.喀麦隆常染色体显性多囊肾病患者的肠道微生物群与肾功能:一项横断面研究。
BMC Nephrol. 2025 Jan 13;26(1):20. doi: 10.1186/s12882-025-03942-6.
6
High interindividual variability of indoxyl sulfate production identified by an oral tryptophan challenge test.口服色氨酸激发试验确定硫酸吲哚酚生成存在高度个体间差异。
NPJ Biofilms Microbiomes. 2025 Jan 13;11(1):15. doi: 10.1038/s41522-025-00651-8.
7
Gut microbiota regulates oxidative stress and inflammation: a double-edged sword in renal fibrosis.肠道微生物群调节氧化应激和炎症:肾纤维化中的双刃剑。
Cell Mol Life Sci. 2024 Dec 5;81(1):480. doi: 10.1007/s00018-024-05532-5.
8
Does the Composition of Gut Microbiota Affect Chronic Kidney Disease? Molecular Mechanisms Contributed to Decreasing Glomerular Filtration Rate.肠道微生物组成是否会影响慢性肾脏病?降低肾小球滤过率的分子机制。
Int J Mol Sci. 2024 Sep 27;25(19):10429. doi: 10.3390/ijms251910429.
9
Indole and p-cresol in feces of healthy subjects: Concentration, kinetics, and correlation with microbiome.健康受试者粪便中的吲哚和对甲酚:浓度、动力学及其与微生物组的相关性。
Front Mol Med. 2022 Sep 21;2:959189. doi: 10.3389/fmmed.2022.959189. eCollection 2022.
10
Investigation of the human-gut-kidney axis by fecal proteomics, highlights molecular mechanisms affected in CKD.通过粪便蛋白质组学对人肠道-肾脏轴进行研究,突出了慢性肾脏病中受影响的分子机制。
Heliyon. 2024 Jun 11;10(12):e32828. doi: 10.1016/j.heliyon.2024.e32828. eCollection 2024 Jun 30.
肠道微生物群与肠-脑轴对色氨酸的代谢:一项分析
Front Neurosci. 2019 Dec 18;13:1365. doi: 10.3389/fnins.2019.01365. eCollection 2019.
4
Tryptophan Dietary Impacts Gut Barrier and Metabolic Diseases.色氨酸饮食对肠道屏障和代谢性疾病的影响。
Front Immunol. 2019 Sep 10;10:2113. doi: 10.3389/fimmu.2019.02113. eCollection 2019.
5
Alterations to the Gut Microbiota and Their Correlation With Inflammatory Factors in Chronic Kidney Disease.肠道微生物群的改变及其与慢性肾脏病中炎症因子的相关性。
Front Cell Infect Microbiol. 2019 Jun 12;9:206. doi: 10.3389/fcimb.2019.00206. eCollection 2019.
6
Butyrate production in patients with end-stage renal disease.终末期肾病患者的丁酸盐生成
Int J Nephrol Renovasc Dis. 2019 May 6;12:87-101. doi: 10.2147/IJNRD.S200297. eCollection 2019.
7
Uremic Toxin Concentrations are Related to Residual Kidney Function in the Pediatric Hemodialysis Population.尿毒症毒素浓度与儿科血液透析人群的残余肾功能相关。
Toxins (Basel). 2019 Apr 24;11(4):235. doi: 10.3390/toxins11040235.
8
Clostridioides difficile Infection in Chronic Kidney Disease/End-Stage Renal Disease.艰难梭菌感染与慢性肾脏病/终末期肾病。
Adv Chronic Kidney Dis. 2019 Jan;26(1):30-34. doi: 10.1053/j.ackd.2019.01.001.
9
Gut microbiota dynamics and uraemic toxins: one size does not fit all.肠道微生物群动态变化与尿毒症毒素:一刀切并不适用。
Gut. 2019 Dec;68(12):2257-2260. doi: 10.1136/gutjnl-2018-317561. Epub 2018 Nov 21.
10
Altered gut microbiota and microbial biomarkers associated with chronic kidney disease.与慢性肾脏病相关的肠道微生物群改变和微生物生物标志物。
Microbiologyopen. 2019 Apr;8(4):e00678. doi: 10.1002/mbo3.678. Epub 2018 Aug 7.